Zhitong Finance App News, Bailey Tianheng (688506.SH) announced that on December 11, 2023, SysTimMune, Inc.'s wholly-owned subsidiary SysTimMune, Inc. and Bristol-Myers Squibb (“BMS”, NYSE code: BMY) reached an exclusive license and cooperation agreement for the BL-B01D1 (EGFR×HER3 dual-antibody ADC) project. On February 8, 2024, the cooperation agreement officially came into effect.
As of March 7, 2024, the company has received a down payment of 800 million US dollars from BMS (the actual payment amount is subject to bank charges), and the company expects this payment to have a positive impact on the 2024 results.